Key result
Dimethyl fumarate reduces cardiac injury markers and improves cellular repair in rats with induced MI.
Its licence doesn't allow us to show a copy here.
Why the study?
Does dimethyl fumarate improve myocardial repair and reduce oxidative stress in a rat model of isoproterenol-induced myocardial infarction?
Does dimethyl fumarate improve myocardial repair and reduce oxidative stress in a rat model of isoproterenol-induced myocardial infarction?
Dimethyl fumarate attenuates post-infarct myocardial injury and enhances cellular repair in a rat model, suggesting potential for pharmacological repurposing in post-infarction recovery.
DMF may limit early biomarker rise in experimental MI; extends preclinical NRG-1 pathway data but leaves clinical translation open.
BACKGROUND Dimethyl fumarate (DMF) is a clinically approved antioxidant and anti-inflammatory agent. This study investigated whether DMF treatment is associated with enhanced myocardial repair after isoproterenol (ISO)-induced myocardial infarction (MI) with a focus on the neuregulin-1 (NRG-1)/ErbB2/protein kinase B (Akt) pathway. METHODS MI was induced in male Sprague-Dawley rats via subcutaneous ISO administration (85 mg/kg, two doses 24 h apart). Rats were assigned to Control, MI, Tween-80, and DMF groups. DMF (25 mg/kg/day, oral) was administered for 21 days, and rats were sacrificed on days 7 and 21 to evaluate early and subacute responses. Serum cardiac injury markers, oxidative stress parameters [total antioxidant-oxidant status (TAS-TOS), and oxidative stress index (OSI)], and cardiac tissue levels of NRG-1, ErbB2, PI3K, and Akt-1 were measured. Histological and immunohistochemical analyses assessed myocardial structure, fibrosis, apoptosis (TUNEL), proliferation (BrdU), and progenitor cell activation (c-Kit). RESULTS DMF significantly reduced serum troponin-I, creatine kinase-MB, and lactate dehydrogenase levels in the early phase. It improved oxidative balance by increasing TAS and reducing TOS and OSI, while increasing myocardial NRG-1, ErbB2, and Akt-1 levels compared to the MI group. Histological analyses showed preserved fiber integrity, reduced fibrosis, and fewer apoptotic nuclei. Increased BrdU- and c-Kit-positive cells indicated enhanced cardiomyocyte proliferation and progenitor cell activation through the subacute phase. CONCLUSION DMF attenuated myocardial injury and was associated with modulation of the NRG-1/ErbB2/Akt signaling pathway, improved redox balance, and enhanced indices of cellular repair across early and subacute post-infarction periods. These findings suggest that DMF may represent a promising candidate for pharmacological repurposing in post-infarction recovery; however, further mechanistic studies are required to confirm causality.
No takes yet. Share an insight, caveat, or question.
Tekin et al. (2026) studied Isoproterenol-induced myocardial infarction. Dimethyl fumarate (DMF) vs. Control, MI, and Tween-80 groups was evaluated on Serum cardiac injury markers, oxidative stress parameters, and cardiac tissue levels of NRG-1, ErbB2, PI3K, and Akt-1. Dimethyl fumarate significantly reduced serum cardiac injury markers and improved oxidative balance and cellular repair in rats with isoproterenol-induced myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: